Predictors of repeat myocardial revascularization for the long-term after percutaneous coronary interventions in patients with combination of coronary artery disease and chronic obstructive pulmonary disease

Abstract


Aim. To assess the influence of concomitant chronic obstructive pulmonary disease (COPD) on the frequency of repeat myocardial revascularization in patients with coronary artery disease (CAD) after percutaneous coronary interventions (PCI), as well as to determine independent predictors of repeat revascularization in patients with concominant COPD. Materials and methods. A prospective cohort study included 646 patients with CAD, of which 254 had concominant COPD. All patients underwent PCI (46.9% for acute coronary syndrome in the main group and 44.9% in the control group. Remaining interventions were elective). The frequency of repeat myocardial revascularization and the time till re-intervention was registered during the follow-up period up to 36 months. Results. COPD increases risk of repeat myocardial revascularization (hazard ratio - HR 1.46; 95% confidence interval - CI 1.03-2.06), repeat PCI (HR 1.62; 95% CI 1.03-2.32) and is accompanied by an earlier onset of re-intervention. An independent predictors of repeat myocardial revascularization in the Cox regression model are: glomerular filtration rate (p=0.001), ankle-brachial index (p=0.004), frequent exacerbations of COPD (p=0.028), total number of coronary artery stenosis (p=0.039) and blood concentration of C-reactive protein (p=0.066). Conclusions. COPD is a significant risk factor of re-intervention after PCI in patients with acute and chronic forms of CAD and leads to its earlier performing. The patients with frequent COPD exacerbations have the highest risk of repeat myocardial revascularization during follow-up.

Full Text

Restricted Access

About the authors

Vitalii K. Zafiraki

Kuban State Medical University

Email: vzaphir@mail.ru
Krasnodar, Russia
D. Sci. (Med.)

Konstantin V. Skaletsky

Scientific Research Institution - Ochapovsky Regional Clinical Hospital №1

Krasnodar, Russia
Cand. Sci. (Med.)

Elena D. Kosmacheva

Kuban State Medical University; Scientific Research Institution - Ochapovsky Regional Clinical Hospital №1

Krasnodar, Russia
D. Sci. (Med.)

References

  1. Naito R, Kasai T. Coronary artery disease in type 2 diabetes mellitus: recent treatment strategies and future perspectives. World J Cardiol 2015; 7 (3): 119-24. doi: 10.4330/wjc.v7.i3.119
  2. Chen Y.Y, Wang J.F, Zhang Y.J et al. Optimal strategy of coronary revascularization in chronic kidney disease patients: a meta-analysis. Eur J Int Med 2013; 24 (4): 354-61. doi: 10.1016/j.ejim.2013.03.010
  3. Șerban R.C, Hadadi L, Șuș I et al. Impact of chronic obstructive pulmonary disease on in-hospital morbidity and mortality in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Int J Cardiol 2017; 243: 437-442. doi: 10.1016/j.ijcard.2017.05.044
  4. Bundhun P.K, Gupta C, Xu G.M. Major adverse cardiac events and mortality in chronic obstructive pulmonary disease following percutaneous coronary intervention: a systematic review and meta-analysis. BMC Cardiovasc Disord 2017; 17 (1): 191. doi: 10.1186/s12872-017-0622-2
  5. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. https://www.volgmed.ru/uploads/files/2013-3/17409-globalnaya_strategiya_diagnostiki_lecheniya_i_profilaktiki_hronicheskoj_obstruktivnoj_bolezni_lyogkih_2011_gold.pdf
  6. Lang R.M, Badano L.P, Mor-Avi V et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2005. https://www.onlinejase.com/article/S0894-7317(14)00745-7/pdf
  7. Mohr F.W, Morice M.C, Kappetein A.P et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381: 629-38. doi: 10.1016/S0140-6736(13)60141-5
  8. King P.T. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin Translat Med 2015; 4: 643-50. doi: 10.1186/s40169-015-0068-z
  9. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67: 957-63. doi: 10.1136/thoraxjnl-2011-201518
  10. Campo G, Pavasini R, Malagù M et al. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc Drugs Ther 2015; 29 (2): 147-57. doi: 10.1007/s10557-014-6569-y
  11. Roversi S, Roversi P, Spadafora G et al. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur J Clin Invest 2014; 44 (1): 93-102. doi: 10.1111/eci.12181
  12. Enriquez J.R, Parikh S.V, Selzer F et al. Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry. Chest 2011; 140 (3): 604-10. doi: 10.1378/chest.10-2644
  13. Campo G, Guastaroba P, Marzocchi A et al. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest 2013; 144 (3): 750-7. doi: 10.1378/chest.12-2313
  14. Lin W.C, Chen C.W, Lu C.L et al. The association between recent hospitalized COPD exacerbations and adverse outcomes after percutaneous coronary intervention: a nationwide cohort study. Int J Chron Obstruct Pulmon Dis 2019; 14: 169-79. doi: 10.2147/COPD.S187345
  15. Dubé B.P, Vermeulen F, Laveneziana P. Exertional Dyspnoea in Chronic Respiratory Diseases: From Physiology to Clinical Application. Arch Broncopneumol 2017; 53 (2): 62-70. doi: 10.1016/j.arbres.2016.09.005

Statistics

Views

Abstract - 7

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies